Skip to main content
Figure 2 | BMC Psychiatry

Figure 2

From: Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies

Figure 2

Comparative efficacy of Concerta ® and Equasym XL ® versus placebo over time in a laboratory school study. Data represent all dose levels combined (Equasym XL® 20, 40, 60 mg; Concerta® 18, 36, 54 mg). Corresponding effect sizes for each timepoint are shown in the table. Originally published in Swanson JM, et al. Pediatrics 2004, 113:e206-e216. Reproduced with permission from Pediatrics, Vol. 113, Page(s) e206–e216, Copyright ©2004 by the AAP. *Equasym XL® was significantly better than Concerta®; †Concerta® was significantly better than Equasym XL®; ‡placebo was significantly better than both Equasym XL® and Concerta®. MCD, Equasym XL®; PERMP, permanent product measure of performance; PLA, placebo; SEM, standard error of the mean; SKAMP, Swanson, Kotkin, Atkins, M-Flynn, Pelham rating scale.

Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us